Tiotropium plus olodaterol provides significant lung-function benefits compared to fluticasone plus salmeterol regardless of prior bronchodilator use

被引：1
|
作者：
Derom, Eric
Beeh, Kai-Michael
Echave-Sustaeta, Jose
Gronke, Lars
Zhai, Dongmei
Bjermer, Leif
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Bronchodilators; COPD; -; management; Airway management;
D O I：
10.1183/13993003.congress-2016.PA978
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA978
引用
收藏
页数：2
相关论文
共 33 条
  • [1] Tiotropium plus Olodaterol Therapy Provides Lung-Function Benefits Over Salmeterol plus Fluticasone Propionate Irrespective Of Prior Ics Treatment: Post Hoc Analyses Of The Energito® Study
    Derom, E.
    Clerisme-Beaty, E.
    Gronke, L.
    Voss, F.
    Zhai, D.
    Bjermer, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [2] Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
    Tamura, Tomohiro
    Satoh, Hiroaki
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2909 - 2909
  • [3] Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone Reply
    Beeh, Kai-Michael
    Derom, Eric
    Echave-Sustaeta, Jose
    Groenke, Lars
    Hamilton, Alan
    Zhai, Dongmei
    Bjermer, Leif
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2910 - 2910
  • [4] TIOTROPIUM PLUS OLODATEROL COMBINATION THERAPY PROVIDES LUNG-FUNCTION BENEFITS WHEN COMPARED TO TIOTROPIUM ALONE, IRRESPECTIVE OF PRIOR TREATMENT WITH A LONG-ACTING BRONCHODILATOR: POST HOC ANALYSES OF TWO 1-YEAR STUDIES
    Buhl, R.
    Abrahams, R.
    Groenke, L.
    Korducki, L.
    Flezar, M.
    Ferguson, G. T.
    THORAX, 2015, 70 : A138 - A139
  • [5] Lung-Function Response To Tiotropium plus Olodaterol In Patients With COPD With β-Agonist Reversibility
    Tashkin, D. P.
    Ferguson, G. T.
    Clerisme-Beaty, E.
    Vob, F.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [6] Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone
    Kurashima, Kazuyoshi
    Hara, Kenichirou
    Yoneda, Kouichirou
    Kanauchi, Tetsu
    Kagiyama, Naho
    Tokunaga, Daido
    Takayanagi, Noboru
    Ubukata, Mikio
    Sugita, Yutaka
    RESPIROLOGY, 2009, 14 (02) : 239 - 244
  • [7] Tiotropium Plus Olodaterol Fixed-Dose Combination Therapy Provides Lung Function Benefits When Compared With Tiotropium Alone, Irrespective Of Prior Treatment With A Long-Acting Bronchodilator: Post Hoc Analyses Of Two 1-Year Studies
    Buhl, R.
    Abrahams, R.
    Gronke, L.
    Korducki, L.
    Flezar, M.
    Ferguson, G. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [8] The Effect of Tiotropium/Olodaterol versus Salmeterol/Fluticasone on Left Ventricular Function and Lung Hyperinflation in Patients with COPD
    Herth, F. J.
    Hohlfeld, J. M.
    Haas, J.
    de la Hoz, A.
    Jin, X.
    Kreitner, K.
    Vogelmeier, C. F.
    Vogel-Claussen, J.
    Watz, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [9] Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: A pilot study
    Bateman, E. D.
    van Dyk, M.
    Sagriotis, A.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (01) : 20 - 25
  • [10] Tiotropium plus Olodaterol Therapy Provides Symptomatic Benefits Irrespective Of Prior Maintenance Treatment: Post Hoc Analyses Of The Otemto® Studies
    Abrahams, R.
    Ferguson, G. T.
    Bjermer, L.
    Gronke, L.
    Vob, F.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
1234